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During 2019 several trials in the field of type 2 diabetes have been published, which report results 
using the term ‘estimand’. This will be an unfamiliar word to many clinicians (and to spellcheck) but 
given that regulatory bodies have endorsed its use, it is likely to become a staple of medical jargon in 
the future. 
Introduction   
Randomised controlled trials (RCT) have been recognised as the gold standard to quantify the 
treatment effect of a new medication because randomisation reduces confounding factors and biases 
at baseline. However, during clinical trials it is inevitable that events occur after the initiation of 
investigational medical product (IMP), which affect the interpretation of the trial results (usually 
termed ‘intercurrent events’)[1]. Intention-to-treat (ITT) analyses have been widely employed in 
clinical trials to assess the clinical effectiveness of the treatment under investigation. The ITT principle 
requires that all randomised participants are included in the final analysis, according to the treatment 
group to which they were originally assigned and regardless of the occurrence of intercurrent 
events[2].  
Intercurrent events may present in many forms, one of the most common in diabetes trials being the 
use of rescue medication[3]. For ethical reasons, patients can receive additional glucose lowering 
medication if they fail to achieve the glucose targets specified in the protocol. If subjects receive 
rescue medication, then glucose-lowering may be achieved but will reflect the combined effect of the 
IMP plus the rescue medication. Other intercurrent events include premature discontinuation of IMP, 
loss to follow-up and death. When a patient discontinues IMP because of adverse events, there will 
be a final glucose outcome, but this will not be due to the trial medication. In contrast, for patients 
who are lost to follow-up or deceased, there will be no observed value at the end of the study. In the 
past, the last observed value before the use of rescue medication, discontinuation of IMP or loss to 
follow-up was analysed (‘carried forward’) as the end-of-trial value. This is known as the ‘last-
observation-carried-forward’ (LOCF) approach and was endorsed by the Food and Drug 
Administration (FDA) in its 2008 guidance[4]. The LOCF approach, however, can overestimate the 
effect of a trial product because it assumes that patients who have a good short-term outcome will 
continue to have a good outcome going forwards[5]. Conversely, LOCF will underestimate an effect 
that only slowly appears if a trial subject drops out early from the study. The 2010 National Research 
Council Report, commissioned by the FDA, acknowledged these deficits and recommended against 
the use of LOCF[6]; this advice was also endorsed by the European Medicines Agency[5].  
The FDA’s former position on the LOCF approach was illustrated in the 2011 public advisory committee 
meeting for dapagliflozin[3]. The trial sponsor excluded data accrued after the initiation of rescue 
medication, aiming to establish the true treatment effect of dapagliflozin. However, the FDA reviewer 
argued that all data should be included regardless of the use of rescue medication. This clearly 
demonstrated that the scientific question of interest can differ according to different stakeholders’ 
perspectives. Trial protocols or publications have previously not completely described the type of 
treatment effect to be estimated, and this has led to difficulty in interpreting data and making 
comparisons of results from other trials. In 2017, the International Council for Harmonisation (ICH) 
Steering Committee published a draft guideline entitled ‘Estimands and sensitivity analysis of clinical 
trials’ (ICH E9 (R1)) and this is now being adopted.  
The estimand concept 
An estimand is “a detailed description of what needs to be estimated to address a specific scientific 
question of interest”[1] and is characterised according to four elements: (a) the population of interest; 
(b) the endpoint of interest; (c) the methods for handling intercurrent events; and (d) the population 
level summary. Traditionally, trial protocols have not explicitly described the third element and the 
ICH E9 (R1) draft paper proposed five different strategies to deal with this:  
a. Treatment policy strategy in which the observed values of a variable are used regardless of 
intercurrent events. This broadly corresponds to the previously recommended ITT analysis. 
b. Hypothetical strategy in which a situation is envisaged where all participants adhered to the 
protocol and do not experience any intercurrent events. 
c. Composite strategy where the intercurrent event is integrated with one or more measures of 
clinical outcome as a combined variable of interest.  
d. Principal stratum strategy where only the subset of the trial population who did not 
experience the intercurrent event is subjected to the analysis. 
e. While on treatment strategy which describes the treatment effect before any intercurrent 
events occurred. In this strategy, the outcomes until the time of the intercurrent event are 
analysed, rather than the value observed at the same fixed timepoints for all participants.  
It should be noted that none of these analyses directly correspond to a per-protocol or complete case 
analysis.  
In 2018 the EMA published draft guidance discussing the specific use of estimands in diabetes trials 
[7]. When investigating the change from baseline HbA1c, the EMA recommends ‘the hypothetical 
strategy’ for the use of rescue medication; the ‘treatment policy strategy’ for premature 
discontinuation of IMP; and the ‘composite strategy’ to account for two intercurrent events through 
definition of the endpoint. Following these recommendations from the FDA and the EMA, several 
diabetes clinical trials have incorporated the estimand concept including three in Lancet Diabetes & 
Endocrinology [8-10]. 
To put these estimands into the context of a diabetes trial (see figure), the hypothetical estimand (also 
termed ‘trial product estimand’) will tell the clinician the glucose-lowering effect of a new treatment 
if the patient is willing and able to take it as directed, whilst the treatment policy estimand will indicate 
how the drug will work in a more real-life setting where drug discontinuation and add-in therapies are 
common (a scenario more relevant to payers). The composite estimand may seek to combine these 
facets, for example patients reaching glycaemic targets whilst adhering to trial product and not taking 
additional therapy. 
An obvious question is how much the trial endpoints are affected when different estimands are 
considered and data are now available. For example, in the PIONEER 5 trial of oral semaglutide versus 
placebo, the mean HbA1c and weight changes from baseline to 26 weeks were -1.1% (-12 mmol/mol) 
and -3.7kg for the hypothetical estimand compared with -1.0% (-11 mmol/mol) and -3.4kg using the 
treatment policy estimand [9]. So, there are the anticipated differences in favour of the hypothetical 
estimand but the magnitude is small for both HbA1c and weight. 
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